BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 25817540)

  • 1. The clinical characteristics and prognosis of IGH deletion in multiple myeloma.
    He H; Fu W; Jiang H; Du J; Zhou L; Zhang C; Xi H; Li R; Hou J
    Leuk Res; 2015 May; 39(5):515-9. PubMed ID: 25817540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Characteristics and Prognosis of MAF Deletion in Chinese Patients With Multiple Myeloma.
    Wang Y; Li Q; Xing S; Zhang H; Li D
    Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):e545-e550. PubMed ID: 31262667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Newly diagnosed multiple myeloma patients carrying monoallelic deletion of the whole locus of immunoglobulin heavy chain gene have a better prognosis compared to those with t(4;14) and t(14;16).
    Duek A; Trakhtenbrot L; Amariglio N; Benyamini N; Zilbershats I; Ganzel C; Shevetz O; Leiba R; Rozic G; Nagler A; Leiba M
    Genes Chromosomes Cancer; 2019 Aug; 58(8):516-520. PubMed ID: 30675954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromosome 13q deletion and IgH abnormalities may be both masked by near-tetraploidy in a high proportion of multiple myeloma patients: a combined morphology and I-FISH analysis.
    Koren-Michowitz M; Hardan I; Berghoff J; Yshoev G; Amariglio N; Rechavi G; Nagler A; Trakhtenbrot L
    Cancer Lett; 2007 Oct; 255(2):307-14. PubMed ID: 17590504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The significances of 13q14 deletion for development and prognosis of multiple myeloma].
    Li Q; An G; Li CW; Xu Y; Deng SH; Liu XP; Qi JY; Wang YF; Zou DH; Zhao YZ; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2011 Apr; 32(4):217-20. PubMed ID: 21569701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma.
    Li F; Xu Y; Deng P; Yang Y; Sui W; Jin F; Hao M; Li Z; Zang M; Zhou D; Gu Z; Ru K; Wang J; Cheng T; Qiu L
    Oncotarget; 2015 Apr; 6(11):9434-44. PubMed ID: 25831238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular cytogenetic aberrations in patients with multiple myeloma studied by interphase fluorescence in situ hybridization.
    Chen L; Li J; Xu W; Qiu H; Zhu Y; Zhang Y; Duan L; Qian S; Lu H
    Exp Oncol; 2007 Jun; 29(2):116-20. PubMed ID: 17704743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of chromosome 13q deletions and IgH translocations in patients with multiple myeloma by FISH: comparison with karyotype analysis.
    Chang H; Li D; Zhuang L; Nie E; Bouman D; Stewart AK; Chun K
    Leuk Lymphoma; 2004 May; 45(5):965-9. PubMed ID: 15291356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deletions and amplifications of the IGH variable and constant regions:a novel prognostic parameter in patients with multiple myeloma.
    Rabani H; Ziv M; Lavi N; Aviv A; Suriu C; Shalata A; Haddid Y; Tadmor T
    Leuk Res; 2020 Dec; 99():106476. PubMed ID: 33171301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Chromosome 13q deletion detected by interphase FISH in multiple myeloma: a study of 100 cases in China].
    Li Q; Lu Y; Wang YF; Liu XP; Qi JY; Zou DH; Zhao YZ; Qiu LG
    Zhonghua Yi Xue Za Zhi; 2009 Jul; 89(28):1979-82. PubMed ID: 19950573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of 13q deletion, trisomy 1q, and IgH rearrangement as the most frequent chromosomal changes found in Korean patients with multiple myeloma.
    Bang SM; Kim YR; Cho HI; Chi HS; Seo EJ; Park CJ; Yoo SJ; Kim HC; Chun HG; Min HC; Oh BR; Kim TY; Lee JH; Lee DS
    Cancer Genet Cytogenet; 2006 Jul; 168(2):124-32. PubMed ID: 16843102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytogenetic Abnormalities in Multiple Myeloma Patients at a Tertiary Healthcare Center in India.
    Govindasamy P; Pandurangan P; Tarigopula A; Mani R; R Samuel C
    Asian Pac J Cancer Prev; 2019 Jan; 20(1):235-241. PubMed ID: 30678438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions.
    Chang H; Sloan S; Li D; Keith Stewart A
    Br J Haematol; 2004 Nov; 127(3):280-4. PubMed ID: 15491286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma.
    Kaufmann H; Ackermann J; Baldia C; Nösslinger T; Wieser R; Seidl S; Sagaster V; Gisslinger H; Jäger U; Pfeilstöcker M; Zielinski C; Drach J
    Leukemia; 2004 Nov; 18(11):1879-82. PubMed ID: 15385925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Various patterns of IgH deletion identified by FISH using combined IgH and IgH/CCND1 probes in multiple myeloma and chronic lymphocytic leukemia.
    Hwang Y; Lee JY; Mun YC; Seong CM; Chung WS; Huh J
    Int J Lab Hematol; 2011 Jun; 33(3):299-304. PubMed ID: 21272268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chromosome 1p21 deletion is a novel prognostic marker in patients with multiple myeloma.
    Chang H; Ning Y; Qi X; Yeung J; Xu W
    Br J Haematol; 2007 Oct; 139(1):51-4. PubMed ID: 17854306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Detection of deletion of the long arm of chromosome 13 and translocation of immunoglobulin heavy chain gene by interphase fluorescence in situ hybridization in patients with multiple myeloma].
    Sun WL; Wu YJ; Li H; Wang X; Zhuang JL
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2008 Aug; 30(4):485-90. PubMed ID: 18795626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between losses of IGH or its segments and deletions of 13q14 in t(11;14) (q13;q32) multiple myeloma.
    Trakhtenbrot L; Hardan I; Koren-Michowitz M; Oren S; Yshoev G; Rechavi G; Nagler A; Amariglio N
    Genes Chromosomes Cancer; 2010 Jan; 49(1):17-27. PubMed ID: 19787791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion.
    Sagaster V; Ludwig H; Kaufmann H; Odelga V; Zojer N; Ackermann J; Küenburg E; Wieser R; Zielinski C; Drach J
    Leukemia; 2007 Jan; 21(1):164-8. PubMed ID: 17096015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma.
    Chang H; Trieu Y; Qi X; Xu W; Stewart KA; Reece D
    Leuk Res; 2007 Jun; 31(6):779-82. PubMed ID: 16996589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.